Compare MMT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | NBP |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.4M | 212.8M |
| IPO Year | N/A | N/A |
| Metric | MMT | NBP |
|---|---|---|
| Price | $4.47 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 109.5K | ★ 563.8K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $1.46 |
| 52 Week High | $4.87 | $5.19 |
| Indicator | MMT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 32.10 |
| Support Level | $4.39 | N/A |
| Resistance Level | $4.69 | $1.95 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 28.95 | 8.86 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, automotive, chemicals, electronics, and others.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.